The impact of venetoclax is predominantly defined by an inhibition of BCL2, not BCLXL or MCL1, and has provided single agents effects, suggesting BCL2 dependence in some MM cells [18]. The gene discussed is BCL2; the disease is Miyoshi myopathy.